Editas Medicine Inc

For the period ended Dec 31, 2024. Filed Mar 5, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 5, 2025

EDIT$2.51-8.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

(amounts in thousands)

	Year Ended December 31,
	2024	2023	2022
Cash flow from operating activities
Net loss	$(237,093)	$(153,219)	$(220,432)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	21,417	19,798	29,294
Depreciation	5,809	6,064	6,337
Net amortization of premiums and discounts on marketable securities	(5,791)	(4,823)	(724)
Loss on disposal of fixed assets	149	—	—
Non-cash interest expense on liability for sale of future revenues	2,190	—	—
Other non-cash items, net	(415)	1,596	—
Changes in operating assets and liabilities:
Accounts receivable	(6,079)	(5,042)	(4,878)
Prepaid expenses and other current assets	4,396	(197)	(137)
Right-of-use assets	1,126	9,968	(17,475)
Other non-current assets	3,366	(3,335)	1,558
Accounts payable	(2,286)	(1,492)	4,368
Accrued expenses	11,623	4,114	10,505
Deferred revenue	(8,463)	—	(3,333)
Operating lease liabilities	(1,504)	(7,410)	17,568
Other current and non-current liabilities	1,271	1,800	—
Net cash used in operating activities	(210,284)	(132,178)	(177,349)
Cash flow from investing activities
Purchases of property and equipment	(8,826)	(4,719)	(4,118)
Proceeds from the sale of equipment	—	—	18
Purchases of marketable securities	(86,217)	(258,517)	(315,186)
Proceeds from maturities of marketable securities	257,189	259,505	433,354
Net cash provided by (used in) investing activities	162,146	(3,731)	114,068
Cash flow from financing activities
Proceeds from offering of common stock, net of issuance costs	—	117,079	—
Proceeds from sale of future revenues, net	55,244
Proceeds from exercise of stock options	193	41	305
Issuance of common stock under benefit plans	590	919	979
Net cash provided by financing activities	56,027	118,039	1,284
Net increase (decrease) in cash, cash equivalents, and restricted cash	7,889	(17,870)	(61,997)
Cash, cash equivalents, and restricted cash, beginning of period	127,529	145,399	207,396
Cash, cash equivalents, and restricted cash, end of period	$135,418	$127,529	$145,399
Cash and cash equivalents, end of period	131,541	123,652	141,522
Restricted cash1	3,877	3,877	3,877
Cash, cash equivalents, and restricted cash, end of period	$135,418	$127,529	$145,399
1As of December 31, 2024, December 31, 2023, and December 31, 2022 restricted cash of $3,877, $3,877, and $3,877, respectively, was included in Restricted cash and other non-current assets on the Consolidated Balance Sheet

Supplemental disclosure of cash and non-cash activities:
Fixed asset additions included in accounts payable and accrued expenses	$65	$845	$1,440
Cash paid in connection with operating lease liabilities	18,447	12,428	14,851
Remeasurement of operating lease liabilities and right-of-use assets due to lease modification	794	2,752	24,545
Commencement of right-of-use asset	7,844	—	5,316
Modification of right-of-use asset	2,683	—	—
Issuance costs associated with the sale of future revenues included in accounts payable and accrued expenses	1,479	—	—

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.